SYNTHESIS AND BIOLOGICAL ACTIVITY OF NOVEL 6-PHENYL-1H-PYRROLO[3,4-c]PYRIDINE-1,3-DIONE DERIVATIVES. 2017

Anna Wojcicka, and Lilianna Becan, and Adam Junka, and Marzenna Brtoszewicz, and Anna Secewicz, and Justyna Trynda, and Joanna Wietrzyk

The new pyrrolo[3,4-c]pyridines have been synthesized. 4-Methyl-6-phenyl-1H-pyrrolo[3,4-cpyridine-1,3-dione (1) was the key intermediate for the synthesis of the novel derivatives of various chemical structures. In the first step, the pyrrolo[3,4-c]pyridine-1,3-dione 1 was alkylated to the corresponding N-alkyl-4- methyl-6-phenyl-IH-pyrrolo[3,4-c]pyridine-1,3-dione derivatives 2a-f. The Mannich bases 3a-j were synthesized by treating pyrrolo[3,4-c]pyridine-1,3-dione 1 with appropriate amines and formaldehyde. Hydrolysis of ester 2a gave the appropriate acid 5. Next, amides 4a-e have been obtained. The structures of the new compounds were confirmed by elemental analysis, IR and NMR spectra. The antitumor and antimicrobial activities in vitro of the obtained derivatives were examined. Mannich bases 3c and 3g showed activity against C. albicans and S. aureus.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D011758 Pyrroles Azoles of one NITROGEN and two double bonds that have aromatic chemical properties. Pyrrole
D002176 Candida albicans A unicellular budding fungus which is the principal pathogenic species causing CANDIDIASIS (moniliasis). Candida albicans var. stellatoidea,Candida stellatoidea,Dematium albicans,Monilia albicans,Myceloblastanon albicans,Mycotorula albicans,Parasaccharomyces albicans,Procandida albicans,Procandida stellatoidea,Saccharomyces albicans,Syringospora albicans
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013211 Staphylococcus aureus Potentially pathogenic bacteria found in nasal membranes, skin, hair follicles, and perineum of warm-blooded animals. They may cause a wide range of infections and intoxications.
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Anna Wojcicka, and Lilianna Becan, and Adam Junka, and Marzenna Brtoszewicz, and Anna Secewicz, and Justyna Trynda, and Joanna Wietrzyk
May 2020, Naunyn-Schmiedeberg's archives of pharmacology,
Anna Wojcicka, and Lilianna Becan, and Adam Junka, and Marzenna Brtoszewicz, and Anna Secewicz, and Justyna Trynda, and Joanna Wietrzyk
January 2003, Acta poloniae pharmaceutica,
Anna Wojcicka, and Lilianna Becan, and Adam Junka, and Marzenna Brtoszewicz, and Anna Secewicz, and Justyna Trynda, and Joanna Wietrzyk
January 2009, Acta poloniae pharmaceutica,
Anna Wojcicka, and Lilianna Becan, and Adam Junka, and Marzenna Brtoszewicz, and Anna Secewicz, and Justyna Trynda, and Joanna Wietrzyk
December 2020, Molecules (Basel, Switzerland),
Anna Wojcicka, and Lilianna Becan, and Adam Junka, and Marzenna Brtoszewicz, and Anna Secewicz, and Justyna Trynda, and Joanna Wietrzyk
April 2016, Bioorganic chemistry,
Anna Wojcicka, and Lilianna Becan, and Adam Junka, and Marzenna Brtoszewicz, and Anna Secewicz, and Justyna Trynda, and Joanna Wietrzyk
February 2012, Acta crystallographica. Section E, Structure reports online,
Anna Wojcicka, and Lilianna Becan, and Adam Junka, and Marzenna Brtoszewicz, and Anna Secewicz, and Justyna Trynda, and Joanna Wietrzyk
September 2016, Molecules (Basel, Switzerland),
Anna Wojcicka, and Lilianna Becan, and Adam Junka, and Marzenna Brtoszewicz, and Anna Secewicz, and Justyna Trynda, and Joanna Wietrzyk
April 2021, Pharmaceuticals (Basel, Switzerland),
Anna Wojcicka, and Lilianna Becan, and Adam Junka, and Marzenna Brtoszewicz, and Anna Secewicz, and Justyna Trynda, and Joanna Wietrzyk
June 2020, Molecules (Basel, Switzerland),
Anna Wojcicka, and Lilianna Becan, and Adam Junka, and Marzenna Brtoszewicz, and Anna Secewicz, and Justyna Trynda, and Joanna Wietrzyk
January 2005, Farmaco (Societa chimica italiana : 1989),
Copied contents to your clipboard!